The compelling Ph2/3 data and clear regulatory path (FDA meeting Q3, BLA Q4 2026) represent a major catalyst for CMPX. Monitor for FDA meeting outcomes and BLA acceptance; the OS crossover analysis provides supportive evidence for regulators. CTX-8371 and CTX-471 pipeline data in H2 2026 provide additional upside optionality.
Price Chart
Executive Summary
Compass Therapeutics furnished an updated corporate presentation disclosing positive Phase 2/3 COMPANION-002 data for tovecimig (DLL4 x VEGF-A) in 2L biliary tract cancer. The trial met its primary endpoint (ORR 18.0% vs 5.3%, p=0.0228) and key secondary PFS endpoint (HR=0.44, p<0.0001). The company plans to meet with the FDA in Q3 2026 and file a BLA in Q4 2026, with potential approval in 2H 2027 targeting a $3B+ US addressable market. The presentation also highlighted early-stage data for pipeline candidates CTX-8371 (PD-1 x PD-L1) and CTX-471 (CD137 agonist).
Key Facts
- COMPANION-002 met primary endpoint: ORR 18.0% (tovecimig + paclitaxel) vs 5.3% (paclitaxel alone), p=0.0228
- Key secondary PFS endpoint met: median PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001)
- OS confounded by crossover: 54% of control patients crossed over; median OS 8.9 vs 9.4 months (HR=1.05, p=0.78)
- Post-hoc crossover analysis showed median OS 12.8 months for crossover patients vs 6.1 months for non-crossover (HR=0.54, p=0.04)
- Company planning FDA meeting in Q3 2026 and BLA submission in Q4 2026; potential approval in 2H 2027
- $195M cash and marketable securities at Q1 2026 with runway into 2028
- $3B+ addressable US market in 2L BTC with potential expansion into gastric, ovarian, CRC, renal, HCC
- Early CTX-8371 data showed deep responses in TNBC, HL, and NSCLC post-checkpoint inhibitor
- CTX-471 identified NCAM (CD56) as potential biomarker; Phase 2 in NCAM+ tumors planned for mid-2026
Financial Impact
Positive Ph2/3 data supports BLA filing for tovecimig in 2L BTC, targeting a $3B+ US market; company has $195M cash runway into 2028
Risk Factors
- OS data confounded by high crossover rate (54%) may be a concern for FDA
- No approved therapeutics in 2L BTC means less precedent for regulatory pathway
- Competition from other 2L BTC therapies could limit market share
- Clinical-stage biotech with no approved products; development and regulatory risks remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004428 |
| Document: f8k_070126.htm | 0001171843-26-004428 |
| Document: 0001171843-26-004428-index-headers.html | 0001171843-26-004428 |
| Document: 0001171843-26-004428-index.html | 0001171843-26-004428 |
| Document: 0001171843-26-004428.txt | 0001171843-26-004428 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7697 | awaiting T+20 | — | $0.7476 (−2.87%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7476 (+39.71%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7476 (−68.85%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7476 (−62.43%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7476 (−62.43%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7476 (−63.53%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7476 (−67.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7476 (−63.17%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7476 (−63.88%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7476 (−61.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers